clinical trial · NCT04023071
FT516 in Subjects With Advanced Hematologic Malignancies
Acute Myelogenous LeukemiaB-cell LymphomaFT516RituximabObinutuzumabCyclophosphamideFludarabineIL-2Bendamustine
brief summary
This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.
started
Oct 4, 2019
primary completion
Oct 23, 2023
completion
Oct 23, 2023
last updated
Oct 26, 2023
official title
A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol